Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 28, 2014
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - November 28, 2014

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

11/28/14 - "Endoprosthesis with Filament Repositioning of Retrieval Member and Guard Structure" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Health& Medicine Week A patent application by the inventors Tupil, Srinath; Biggins, James; Bertolino, William, filed on July 21, 2014, was made available online on November 13, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned
11/28/14 - Active Pharmaceutical Ingredients (API) Global Market - Forecast to 2020
Research and Markets has announced the addition of the "Active Pharmaceutical Ingredients Global Market- Forecast to 2020" report to their offering. Active Pharmaceutical Ingredients are active substances used in pharmaceutical drug product intended to achieve pharmacological activity or induce beneficial health effects by having direct effect on
11/28/14 - Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Generic Clearance for the...
Also include the FDA docket number found in brackets in the heading of this document. SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. In order to conduct educational and public information programs relating to tobacco use as authorized
11/28/14 - Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, has entered into a Securities Purchase Agreement with Deerfield Management and certain of its affiliates pursuant to which Alimera will issue shares of preferred stock to Deerfield with a
11/28/14 - Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board [Kuwait News Agency]
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today the addition of Steven Opal, M.D., an internationally recognized key opinion leader in the areas of pneumonia and sepsis, to the Company's scientific advisory board. Opal is a Professor of..
11/28/14 - AstraZeneca Pharmaceuticals, Amylin Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., Nov. 28 AstraZeneca Pharmaceuticals, Wilmington, Delaware, and Amylin Pharmaceuticals, San Diego, have been assigned a patent developed by 16 co-inventors for "GIP and exendin hybrid polypeptides." The co-inventors are Odile Esther Levy, San Diego, Alain D. Baron, San Diego, Lawrence J. D'Souza, San Diego, Mary Erickson, San Dieg
11/28/14 - AstraZeneca Pharmaceuticals, Amylin Pharmaceuticals Assigned Patent for Sustained Release Formulations Using Non-aqueous Carriers
ALEXANDRIA, Va., Nov. 28 AstraZeneca Pharmaceuticals, Wilmington, Delaware, and Amylin Pharmaceuticals, San Diego, have been assigned a patent developed by six co-inventors for the "sustained release formulations using non-aqueous carriers." The co-inventors are Mary L. Houchin, Rockville, Maryland, Robin H. Lee, San Diego, Hong Qi, San Diego, Gr
11/28/14 - AVANIR PHARMACEUTICALS, INC. FILES (8-K) Disclosing Other Events, Financial Statements and Exhibits
On November 26, 2014, Avanir Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration has issued a Complete Response letter to its New Drug Application for AVP-825. A copy of the Press Release is filed herewith as Exhibit 99.1 and is incorporated by reference herein. Description 99.1 Press Release, dated No
11/28/14 - BioMarin agrees to buy Dutch biotech company for up to $840 million [The Marin Independent Journal, Novato, Calif.]
Nov. 28 BioMarin agreed this week to buy Dutch biotech company Prosensa Holding N.V., a move intended to expand the Marin- based company's repertoire of drugs that fight rare diseases. It is under review by the U.S. Food and Drug Administration as is being fast-tracked for approval, BioMarin officials said. The deal also includes two additional $
11/28/14 - Cephalon Assigned Patent
ALEXANDRIA, Va., Nov. 28 Cephalon, Frazer, Pennsylvania, has been assigned a patent developed by Jason Edward Brittain, El Cajon, California, and Joe Craig Franklin, Tulsa, Oklahoma, for bendamustine pharmaceutical compositions. The patent application was filed on Dec. 19, 2012. Written by Sudarshan Harpal; edited by Jaya Anand.
11/28/14 - Cipla announces a distribution agreement with Serum Institute of India for affordable paediatric vaccines in Europe
Under the agreement, SII will develop and manufacture paediatric vaccines, Cipla will seek European Medicines Agency approval and market the products in Europe. This collaboration with SII enables Cipla to enter into the vaccines segment, continuing our commitment to inclusive healthcare for the world. Subhanu Saxena, MD& Global CEO, Cipla Limited
11/28/14 - Clinical trial for brain cancer treatment [Global Data Point]
The patients will be treated at the Royal Brisbane and Women's Hospital and the Austin Hospital in Melbourne.&# x0D;. "The treatment involves an antibody that targets a cancer protein on the surface of tumour cells," Dr Day said&# x0D;. Dr Stringer said the upcoming GBM trial would be the first test of the drug against solid tumours, as opposed to
11/28/14 - Company Profile for Highland Therapeutics Inc.
Highland Therapeutics Inc. is a specialty pharmaceutical company that, through its wholly owned subsidiary Ironshore Pharmaceuticals& Development, Inc., is leveraging its proprietary technology, DELEXIS?, to optimize the delivery of previously approved drug products. The Company's lead product candidates, HLD-200 and HLD-100, are novel formulatio
11/28/14 - Concordia Healthcare Corp. Provides Clinical Trial and Corporate Update
-Concordia Healthcare Corp.,, announced today a clinical trial and corporate update, including the status of patient enrollment in its Phase 3 clinical trial to treat a rare form of bile duct cancer, and the entering into of an exclusive trademark license and product distribution agreement for China and other Asian territories with Union Med.
11/28/14 - Govt urged to take steps forpromoting pharma industry
The office bearers of PPMA have said that government should take positive measurers to promote pharma industry instead of harassing them. They strongly condemned violation of drug act and unlawful action taken by the Health Department. The meeting was attended by Mian Asad Shujaur Rehman, Khawaj Shahzeb Akram, Akbar Ali Bhatti, Amjad Ali Jawa and H
11/28/14 - High Hope for New Ebola Vaccine
The update also mentioned that the results were published on Wednesday in the New England Journal of Medicine. "The safety profile is encouraging, as is the finding that the higher dose of vaccine induced an immune response quite comparable to that which has completely protected animals from Ebola," said Dr Anthony Fauci, Director of the US Nation
11/28/14 - Ipsen Announces FDA Acceptance of Filing for Dysport in the Treatment of Upper Limb Spasticity in Adult Patients
Ipsen today announced that the U.S. Food and Drug Administration has accepted for review its supplemental Biologics License Application for Dysport in the treatment of upper limb spasticity in adult patients. Marc de Garidel, Chairman and Chief Executive Officer of Ipsen stated The filing of Dysport in adult upper limb spasticity is an imp
11/28/14 - Janssen submits NDA for YONDELIS to FDA to treat advanced soft tissue sarcoma [EMBIN (Emerging Markets Business Information News]
Janssen Research& Development has submitted a new drug application for YONDELIS to the US Food and Drug Administration for the treatment of patients with advanced soft tissue sarcoma, including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy including an anthracycline. We are particularly proud of this filing, as it...
11/28/14 - Just Published: "Medisyn Technologies, Inc. - Product Pipeline Review - 2014"
New Pharmaceuticals market report from Global Markets Direct: " Medisyn Technologies, Inc.- Product Pipeline Review- 2014". Boston, MA 11/28/2014 Global Markets Direct's,' Medisyn Technologies, Inc.- Product Pipeline Review- 2014', provides an overview of the Medisyn Technologies, Inc.' s pharmaceutical research and development focus. This re
11/28/14 - Long wait yet for Ebola vaccine [New Vision (Uganda)]
It will be months, at least, before a vaccine becomes available to tackle Ebola, experts have said as researchers reported success in early, safety tests with a leading candidate. A Phase I trial with the virus-based prophylactic carried by chimps showed it was "well-tolerated" by 20 healthy adults who generated antibodies and immune cells in respo
11/28/14 - Market Report, "IkerChem S.L. - Product Pipeline Review - 2014", Published
New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research. Boston, MA 11/28/2014 Global Markets Direct's,' IkerChem S.L.- Product Pipeline Review- 2014', provides an overview of the IkerChem S.L.' s pharmaceutical research and development focus. This report provides comprehensive information on
11/28/14 - Market Report, "Orion Oyj - Product Pipeline Review - 2014", Published
New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market ResearchBoston, MA 11/28/2014 Global Markets Direct's,' Orion Oyj- Product Pipeline Review- 2014', provides an overview of the Orion Oyj's pharmaceutical research and development focus. This report provides comprehensive information on the current
11/28/14 - Market Report, "Orphan Drug Market Access: Payer Insights on the Present and Future", Published
New Pharmaceuticals research report from FirstWord Pharma is now available from Fast Market ResearchBoston, MA 11/28/2014 Orphan Drug Market Access: Payer Insights on the Present and Future is a report that examines the regulation, pricing, reimbursement, players and stakeholder/payer interests that are shaping the current and future directio
11/28/14 - Medicines for Malaria Venture announces collaborations with Cipla and Strides; Collaborations set to advance life-saving pre-referral treatment for severe malaria
Release date- 27112014- Switzerland and India,: Medicines for Malaria Venture signs collaboration agreements with two Indian pharmaceutical companies, Cipla Limited and Strides Arcolab Limited for the development of rectal artesunate for pre-referral treatment of children with severe malaria. Cipla and Strides will each develop a product building o
11/28/14 - Meeting essential needs [China Daily: Europe Weekly]
Essential drugs, or basic medicines, refers to a variety of medicines that are covered by the urban employee medical insurance in China. Merck Serono, a pharmaceutical company headquartered in Darmstadt, Germany, is actively involved in China's ongoing healthcare reforms, during which the essential drugs list is being revised. Allan Gabor, its pres
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Newest and Most Current Medications in the Treatment of Diabetes
This lesson is supported by:
RxSchool
HIV & AIDS Testing & Reporting Guidelines
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415